Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis

Author(s): Shuo Li, Haiyan Zhou, Xiqin Zhang, Bing Bu, Rongjie Tao, Hui Zhang* and Jinming Yu*

Volume 18, Issue 4, 2023

Published on: 08 December, 2022

Page: [528 - 537] Pages: 10

DOI: 10.2174/1574892818666221122114753

Price: $65

Abstract

Background: Thymic epithelial tumors (TETs) are rare thoracic malignancies with no standard second-line treatment. Tumor angiogenesis is closely associated with the pathogenesis and invasiveness of TETs. Anlotinib is a small-molecule multitarget tyrosine kinase inhibitor (TKI) which inhibits tumor angiogenesis and tumor cell proliferation. Published studies have demonstrated the promising clinical effect of multitarget TKIs sunitinib and lenvatinib in previously treated TETs. However, TKIs have a high incidence of adverse events (AEs).

Objective: In this study, we investigated the clinical efficacy and safety of anlotinib in previously treated TET patients.

Methods: We collected clinical data of 22 patients from Shandong Cancer Hospital and Institute between October 2018 and March 2022. These patients were diagnosed with advanced TETs and received at least the first-line (1st-line) treatment. We analyzed the clinical effects between anlotinib monotherapy and anlotinib combination therapy in the second-line (2nd-line) or anlotinib treatment in different lines.

Results: These 22 patients included 18 cases of thymic carcinoma (TC) and 4 cases of thymoma (T). 68.2% of patients were males, and the median age was 53 years. Fourteen patients (63.6%) received anlotinib monotherapy and 8 patients (36.4%) received anlotinib combination therapy. The objective response rate (ORR) was 9.1% in the overall patients. The median progression-free survival (PFS) in the overall population was 12 months (14 months for T and 9 months for TC), and the median overall survival (OS) was 24 months (survival was not reached for T and was 24 months for TC). The incidence of AEs was 50%, most of them were grades I and II, and the incidence of grades III and IV AEs was 9%.

Conclusion: This is the first study reporting the clinical effect of anlotinib in previously treated TETs patients. The survival data indicate that the efficacy of anlotinib is superior to sunitinib and lenvatinib. Our results suggest that anlotinib is a promising treatment option for previously treated TET patients and its toxicity is tolerable. More research and patents are needed in the future to explore better options for the diagnosis and treatment of TETs.

« Previous Next »
[1]
Yokoi K, Kondo K, Fujimoto K, et al. et al. JLCS medical practice guidelines for thymic tumors: summary of recommendations. Jpn J Clin Oncol 2017; 47(12): 1119-22.
[http://dx.doi.org/10.1093/jjco/hyx138] [PMID: 29036455]
[2]
Marx A, Chan JKC, Coindre JM, et al. et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol 2015; 10(10): 1383-95.
[http://dx.doi.org/10.1097/JTO.0000000000000654] [PMID: 26295375]
[3]
Margaritora S, Cesario A, Cusumano G, et al. et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010; 89(1): 245-52.
[http://dx.doi.org/10.1016/j.athoracsur.2009.08.074] [PMID: 20103246]
[4]
Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, Committee EG. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl. 5): v40-55.
[http://dx.doi.org/10.1093/annonc/mdv277] [PMID: 26314779]
[5]
Bluthgen MV, Boutros C, Fayard F, Remon J, Planchard D, Besse B. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. Lung Cancer 2016; 99: 111-6.
[http://dx.doi.org/10.1016/j.lungcan.2016.06.020] [PMID: 27565923]
[6]
Gbolahan OB, Porter RF, Salter JT, et al. et al. A Phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. J Thorac Oncol 2018; 13(12): 1940-8.
[http://dx.doi.org/10.1016/j.jtho.2018.07.094] [PMID: 30121390]
[7]
Merveilleux du Vignaux C, Dansin E, Mhanna L, et al. Systemic therapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol 2018; 13(11): 1762-70.
[http://dx.doi.org/10.1016/j.jtho.2018.08.005] [PMID: 30138763]
[8]
Zucali PA, De Pas T, Palmieri G, et al. et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 2018; 36(4): 342-9.
[http://dx.doi.org/10.1200/JCO.2017.74.4078] [PMID: 29240542]
[9]
Cimpean AM, Raica M, Encica S, Cornea R, Bocan V. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008; 190(3): 238-45.
[http://dx.doi.org/10.1016/j.aanat.2007.05.003] [PMID: 18356031]
[10]
Tomita M, Matsuzaki Y, Edagawa M, et al. et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 2002; 124(3): 493-8.
[http://dx.doi.org/10.1067/mtc.2002.124389] [PMID: 12202865]
[11]
Sasaki H, Kobayashi Y, Nakashima Y, et al. et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001; 31(11): 1038-40.
[http://dx.doi.org/10.1007/s005950170021] [PMID: 11766079]
[12]
Remon J, Girard N, Mazieres J, et al. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. Lung Cancer 2016; 97: 99-104.
[http://dx.doi.org/10.1016/j.lungcan.2016.04.024] [PMID: 27237035]
[13]
Sato J, Satouchi M, Itoh S, et al. et al. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 2020; 21(6): 843-50.
[http://dx.doi.org/10.1016/S1470-2045(20)30162-5] [PMID: 32502444]
[14]
Thomas A, Rajan A, Berman A, et al. et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015; 16(2): 177-86.
[http://dx.doi.org/10.1016/S1470-2045(14)71181-7] [PMID: 25592632]
[15]
Xie C, Wan X, Quan H, et al. et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor. Cancer Sci 2018; 109(4): 1207-19.
[http://dx.doi.org/10.1111/cas.13536] [PMID: 29446853]
[16]
Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 2021; 18(8): 527-40.
[http://dx.doi.org/10.1038/s41571-021-00496-y] [PMID: 33833434]
[17]
Liu S, Qin T, Liu Z, et al. et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis 2020; 11(5): 309.
[http://dx.doi.org/10.1038/s41419-020-2511-3] [PMID: 32366856]
[18]
Palakurthi S, Kuraguchi M, Zacharek SJ, et al. et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumorintrinsic induction of antitumor immunity. cancer immunol Res 2019; 7(9): 1457-71. http://dx.doi.org/10.1158/2326-6066.CIR-18-0595 PMID: 31331945 2019.
[19]
Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. (Review) Oncol Lett 2020; 20(2): 1001-14.
[http://dx.doi.org/10.3892/ol.2020.11685] [PMID: 32724339]
[20]
Zuo R, Zhang C, Lin L, et al. et al. Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review. Thorac Cancer 2020; 11(11): 3383-7.
[http://dx.doi.org/10.1111/1759-7714.13658] [PMID: 32997432]
[21]
Qin W, Zou B, Fan X, Fan B, Wang S, Wang L. Transformation from small cell to squamous cell carcinoma in a thymic carcinoma patient with a durable response to anlotinib: a case report. cancer Manag Res 2022; 14: 1595-602.
[http://dx.doi.org/10.2147/CMAR.S362858] [PMID: 35521088]
[22]
Watanabe K, Shinkai M, Goto H, et al. et al. Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature. Tumori 2013; 99(4): e172-6.
[http://dx.doi.org/10.1177/030089161309900428] [PMID: 24326856]
[23]
Tateishi K, Ko R, Shukuya T, et al. et al. Clinical outcomes of second-line chemotherapy in patients with previously treated advanced thymic carcinoma: a retrospective analysis of 191 patients from the NEJ023 Study. Oncologist 2020; 25(4): e668-74.
[http://dx.doi.org/10.1634/theoncologist.2019-0593] [PMID: 31771990]
[24]
Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T. Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer 2016; 16(1): 156.
[http://dx.doi.org/10.1186/s12885-016-2159-7] [PMID: 26915359]
[25]
Cho J, Kim HS, Ku BM, et al. et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol 2019; 37(24): 2162-70.
[http://dx.doi.org/10.1200/JCO.2017.77.3184] [PMID: 29906252]
[26]
Giaccone G, Kim C. durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up. J Thorac Oncol 2021; 16(3): 483-5.
[http://dx.doi.org/10.1016/j.jtho.2020.11.003] [PMID: 33248322]
[27]
Giaccone G, Kim C, Thompson J, et al. et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018; 19(3): 347-55.
[http://dx.doi.org/10.1016/S1470-2045(18)30062-7] [PMID: 29395863]
[28]
Katsuya Y, Horinouchi H, Seto T, et al. et al. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 2019; 113: 78-86.
[http://dx.doi.org/10.1016/j.ejca.2019.03.012] [PMID: 30991261]
[29]
Rajan A, Heery CR, Thomas A, et al. et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer 2019; 7(1): 269.
[http://dx.doi.org/10.1186/s40425-019-0723-9] [PMID: 31639039]
[30]
Bedekovics J, Beke L, Mokanszki A, Szilagyi S, Mehes G. Programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors. Appl Immunohistochem Mol Morphol 2020; 28(1): 1-9.
[http://dx.doi.org/10.1097/PAI.0000000000000699] [PMID: 30499814]
[31]
Song X, Fan J, Zhu L, Wang Z, He Y, Zhou C. The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review. J Thorac Dis 2021; 13(8): 5093-103.
[http://dx.doi.org/10.21037/jtd-21-290] [PMID: 34527346]
[32]
Williams E. KMT2A-MAML2 fusion molecules and uses thereof. US20220290253. 2022.
[33]
Williams E. KMT2A-MAML2 fusion molecules and uses thereof. US20220290253, 2021.
[34]
Dudakov J, Van D, Brink M, Hanash A. Methods of use for IL-22 promoting rejuvenation of thymic and bone marrow function. US20140248235, 2014.
[35]
Irla M, Lopes N. Methods of boosting thymic regeneration in patients suffering from a thymic injury by using RANKL. US20220265768, 2022.
[36]
Dudakov J, Van D, Brink M, Wertheimer T. Use of BMP4 for thymic regeneration. 10619134, 2020.
[37]
Dudakov J, Van D, Brink M, Hanash A. Methods of use for IL-22 promoting rejuvenation of thymic and bone marrow function. 9119824, 2015.
[38]
Serwold T, Lee RT, Wagers A. Thymic Regeneration. US20160120945, 2016.
[39]
Reinherz EL, Sasada T, Wang J. Polypeptides and methods for thymic vaccination. US20030082156, 2003.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy